Skip to content

Released Nov 4, 2025, before the open

10-Q filed Nov 4, 2025, 37 days after period end · 0000078003-25-000150

Q3 2025 · 10-Q
Revenue$16.65B−5.9% vs Q3 2024+13.7% vs Q2 2025
Net Income$3.54B−20.7% vs Q3 2024+21.7% vs Q2 2025
EPS Diluted$0.62−20.5% vs Q3 2024+21.6% vs Q2 2025
Operating Cash Flowderived$4,603,000,000−31.4%
Free Cash Flowderived$4,001,000,000−34.0%
Margins · derived
Net margin21.3%−4.0 pt vs Q3 2024

What the release said

The release

Same quarter

MetricQ3 2025Q3 2024Q3 2023Q3 2022
Revenue$16.65B$17.70B$13.49B$22.64B
Net Income$3.54B$4.47B-$2.38B$8.61B
EPS Diluted$0.62$0.78-$0.42$1.51

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Pfizer Inc · CIK 78003 · Engraved from SEC EDGAR